Giuseppe Remuzzi, Carlos Chiurchiu, Piero Ruggenenti

Slides:

Advertisements

Similar presentations

Chronic Kidney Disease in Diabetes

Advertisements

MariLia Bahiense Oliveira, Joao Egidio Romao, Roberto Zatz

Anemia management in chronic kidney disease

Mitchell H. Rosner, W. Kline Bolton Kidney International

No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease Kevin E. Chan, Ravi I. Thadhani,

Volume 83, Issue 3, Pages (March 2013)

End-stage renal disease prevention strategies in Latin America

Management of hypertension in patients with chronic kidney disease

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure Steven Fishbane, Nobuyuki Miyawaki Kidney International

Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani

Peter Rossing, Philip Hougaard, Hans-Henrik Parving

Haiyan Wang, Luxia Zhang, Jicheng Lv Kidney International

Francesco Paolo Schena Kidney International

Volume 81, Issue 7, Pages (April 2012)

Need for better diabetes treatment for improved renal outcome

Volume 63, Issue 3, Pages (March 2003)

Volume 70, Pages S21-S25 (December 2006)

Volume 57, Pages S32-S37 (April 2000)

Steven G. Coca, Swathi Singanamala, Chirag R. Parikh

Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease Johannes F.E. Mann, Qi-Long.

C.Y. Hsu, J.D. Ordoñez, G.M. Chertow, D. Fan, C.E. McCulloch, A.S. Go

Anemia as a risk factor for chronic kidney disease

Comorbidity and confounding in end-stage renal disease

Per-Ola Attman, M.D, Petar Alaupovic, Ola Samuelsson

Volume 70, Issue 11, Pages (December 2006)

Volume 55, Issue 3, Pages (March 1999)

Long-term outcomes in nondiabetic chronic kidney disease

Stephen P. McDonald Kidney International Supplements

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease S. Bianchi, R. Bigazzi, V.M. Campese

Volume 70, Issue 12, Pages (December 2006)

Volume 67, Pages S48-S51 (January 2005)

Volume 65, Issue 6, Pages (June 2004)

Volume 86, Issue 3, Pages (September 2014)

Volume 57, Issue 1, Pages (January 2000)

Alfonso M. Cueto-Manzano, Héctor R

Linda F. Fried, Trevor J. Orchard, Bertram L. Kasiske

Proteinuria and hypertensive nephrosclerosis in African Americans

Non-immunologic intervention in chronic allograft nephropathy

The future of renoprotection: Frustration and promises

Methods for guideline development

The kidney, a cardiovascular risk marker, and a new target for therapy

The global challenge of chronic kidney disease

KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target American.

V.R. Sørensen, P.M. Hansen, J. Heaf, B. Feldt-Rasmussen

Lynda Anne Szczech, Ira L. Lazar Kidney International

Volume 63, Issue 5, Pages (May 2003)

A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease S. Susan Hedayati, Venkata Yalamanchili,

Volume 58, Issue 5, Pages (November 2000)

Volume 66, Pages S18-S21 (November 2004)

Opportunities for a chronic disease outreach program in China

Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors Barry M. Brenner, Joann Zagrobelny

ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: The African American Study of Kidney Disease and Hypertension (AASK) trial

Carmine Zoccali, Francesca Mallamaci Kidney International

Clinical benefits of slowing the progression of renal failure

The Danish Renal Biopsy Register

Volume 80, Issue 10, Pages (November 2011)

Volume 60, Issue 3, Pages (September 2001)

Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension Julian Segura, Carlos Campo, Luis M. Ruilope Kidney.

Michael R. Lattanzio, Matthew R. Weir Kidney International

Is it the low-protein diet or simply the salt restriction?

Volume 68, Pages S87-S94 (August 2005)

Cardiovascular risk in chronic kidney disease

Charles A. Herzog Kidney International

Is complement a target for therapy in renal disease?

Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular.

The future of renoprotection

Volume 75, Issue 7, Pages (April 2009)

Volume 53, Issue 5, Pages (May 1998)

Volume 60, Issue 2, Pages (August 2001)

Volume 57, Pages S44-S48 (April 2000)

Presentation transcript:

Proteinuria predicting outcome in renal disease: Nondiabetic nephropathies (REIN) Giuseppe Remuzzi, Carlos Chiurchiu, Piero Ruggenenti Kidney International Volume 66, Pages S90-S96 (November 2004) DOI: 10.1111/j.1523-1755.2004.09221.x Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 1 Risk ratios (and 95% confident intervals) of ESRD or death in a meta-analysis of 11 trials of 1594 patients with nondiabetic renal disease randomized to ACE inhibitor therapy or placebo. Modified from26. Kidney International 2004 66, S90-S96DOI: (10.1111/j.1523-1755.2004.09221.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 2 Rate of GFR decline at interim analysis of 177 patients with nondiabetic chronic nephropathies included in the REIN study, according to baseline proteinuria and treatment randomization. Kidney International 2004 66, S90-S96DOI: (10.1111/j.1523-1755.2004.09221.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 3 Relative risks of ESRD on ACE inhibition therapy or placebo according to different levels of baseline proteinuria in patients with nondiabetic chronic nephropathies enrolled in the REIN Stratum 2 study (left panel) or in the AIPRD meta-analysis (right panel). Kidney International 2004 66, S90-S96DOI: (10.1111/j.1523-1755.2004.09221.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 4 Renal outcomes according to changes in urinary proteins in a pooled analysis of 2387 patients with nondiabetic chronic nephropathies included in 11 randomized trials of different renoprotective treatments. Modified from33. Kidney International 2004 66, S90-S96DOI: (10.1111/j.1523-1755.2004.09221.x) Copyright © 2004 International Society of Nephrology Terms and Conditions